[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffJ8lmbhnRBGnL0Fk4PSXHzrII7Ks5NzBYSVhIHbcU8o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"Seqirus",[4],53,false,1,20,117179,2,0,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Influenza",26,{"name":18,"count":19},"Influenza, Human",23,{"name":21,"count":22},"Virus Diseases",4,{"name":24,"count":25},"Infections",3,{"name":27,"count":25},"Respiratory Tract Infections",{"name":29,"count":11},"Influenza Caused by the Novel Influenza A (H1N1) Virus",{"name":31,"count":11},"Infection Viral",{"name":33,"count":11},"Human",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06087640","A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","2026-11","aQIV or aTIV",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,71,89,155,189,211,235,253,275,296,314,337,362,408,448,483,505,533,567,603,640,666,684,710,728,746,764,782,800,818,836,861,879,897,924,942,960,978,996,1014,1055,1098,1120,1153,1186,1204,1222,1240,1267,1285,1303,1321,1349,1367,1385,1403,1428,1446,1468,1486,1510,1541,1559,1577,1595,1613,1631,1649,1675,1693,1711,1740,1758,1776,1794,1812,1830,1856,1874,1892,1910,1928,1946,1964,1982,2000,2018,2036,2054,2072,2107,2125,2143,2161,2179,2197,2215,2233,2251,2269,2287,2305,2328,2354,2379],{"intervention":39,"totalTrials":8,"cells":49},{"EARLY_PHASE1":50,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":67,"NA":69},{"trials":51,"activeCount":12},[],{"trials":53,"activeCount":12},[],{"trials":55,"activeCount":12},[],{"trials":57,"activeCount":8,"soonestReadout":38},[58],{"nctId":36,"briefTitle":37,"status":59,"phases":60,"primaryCompletion":38,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"ACTIVE_NOT_RECRUITING",[44],"2026-12","2023-10-23",35800,[18],[39,66],"QIV or TIV",{"trials":68,"activeCount":12},[],{"trials":70,"activeCount":12},[],{"intervention":66,"totalTrials":8,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":85,"NA":87},{"trials":74,"activeCount":12},[],{"trials":76,"activeCount":12},[],{"trials":78,"activeCount":12},[],{"trials":80,"activeCount":8,"soonestReadout":38},[81],{"nctId":36,"briefTitle":37,"status":59,"phases":82,"primaryCompletion":38,"completion":61,"start":62,"enrollment":63,"conditions":83,"interventions":84},[44],[18],[39,66],{"trials":86,"activeCount":12},[],{"trials":88,"activeCount":12},[],{"intervention":90,"totalTrials":22,"cells":91},"Trivalent Influenza Vaccine",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":115,"PHASE3":129,"PHASE4":142,"NA":153},{"trials":93,"activeCount":12},[],{"trials":95,"activeCount":12},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":104,"interventions":105},"NCT00848848","Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older","COMPLETED",[42],"2009-04","2008-10",450,[15],[90,106,107,108,109,110,111,112,113,114],"Trivalent Influenza Vaccine + high A","Trivalent Influenza Vaccine + ¼ dose adjuvant","Trivalent Influenza Vaccine + high A + ¼ dose adjuvant","Trivalent Influenza Vaccine + ½ dose adjuvant","Trivalent Influenza Vaccine + high A + ½ dose adjuvant","Trivalent Influenza Vaccine + adjuvant","Trivalent Influenza Vaccine + high A + adjuvant","Trivalent Influenza Vaccine intradermal dose","Trivalent Influenza Vaccine + high A intradermal dose",{"trials":116,"activeCount":12},[117],{"nctId":118,"briefTitle":119,"status":99,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT02035696","Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old",[42,43],"2014-06","2014-12","2013-12",671,[15],[127,128],"Trivalent influenza vaccine","Trivalent influenza vaccine-licensed",{"trials":130,"activeCount":12},[131],{"nctId":132,"briefTitle":133,"status":99,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},"NCT02214225","A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.",[44],"2014-11","2015-04","2014-08",3484,[18],[141,90,90],"Quadrivalent Influenza Vaccine",{"trials":143,"activeCount":12},[144],{"nctId":145,"briefTitle":146,"status":99,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"NCT01863433","A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013\u002F2014 Formulation of Enzira® Vaccine in Healthy Volunteers",[45],"2013-06","2013-05",120,[18],[90],{"trials":154,"activeCount":12},[],{"intervention":156,"totalTrials":11,"cells":157},"CSL Limited Influenza Virus Vaccine",{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":187},{"trials":159,"activeCount":12},[],{"trials":161,"activeCount":12},[],{"trials":163,"activeCount":12},[],{"trials":165,"activeCount":12},[],{"trials":167,"activeCount":12},[168,178],{"nctId":169,"briefTitle":170,"status":99,"phases":171,"primaryCompletion":172,"completion":173,"start":102,"enrollment":174,"conditions":175,"interventions":176},"NCT00735475","A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine",[45],"2009-01","2009-06",1268,[15],[156,177],"US Licensed Influenza Virus Vaccine",{"nctId":179,"briefTitle":180,"status":99,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT00825162","Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to \u003C 18 Years",[45],"2010-02","2009-03",1992,[15],[156,156,156],{"trials":188,"activeCount":12},[],{"intervention":190,"totalTrials":8,"cells":191},"Inactivated Influenza Vaccine",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":209},{"trials":193,"activeCount":12},[],{"trials":195,"activeCount":12},[],{"trials":197,"activeCount":12},[],{"trials":199,"activeCount":12},[],{"trials":201,"activeCount":12},[202],{"nctId":203,"briefTitle":204,"status":99,"phases":205,"primaryCompletion":206,"completion":206,"start":206,"enrollment":150,"conditions":207,"interventions":208},"NCT00888381","A Study to Assess the Immunogenicity and Safety of CSL's 2009 \u002F 2010 Formulation of Enzira® Vaccine in Healthy Volunteers",[45],"2009-05",[15],[190],{"trials":210,"activeCount":12},[],{"intervention":212,"totalTrials":8,"cells":213},"bioCSL Trivalent Influenza Virus Vaccine",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":233},{"trials":215,"activeCount":12},[],{"trials":217,"activeCount":12},[],{"trials":219,"activeCount":12},[],{"trials":221,"activeCount":12},[],{"trials":223,"activeCount":12},[224],{"nctId":225,"briefTitle":226,"status":99,"phases":227,"primaryCompletion":122,"completion":122,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT02212106","A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to \u003C 9 Years",[45],"2014-09",402,[18],[212,232],"Comparator Quadrivalent Influenza Virus Vaccine",{"trials":234,"activeCount":12},[],{"intervention":232,"totalTrials":8,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":251},{"trials":238,"activeCount":12},[],{"trials":240,"activeCount":12},[],{"trials":242,"activeCount":12},[],{"trials":244,"activeCount":12},[],{"trials":246,"activeCount":12},[247],{"nctId":225,"briefTitle":226,"status":99,"phases":248,"primaryCompletion":122,"completion":122,"start":228,"enrollment":229,"conditions":249,"interventions":250},[45],[18],[212,232],{"trials":252,"activeCount":12},[],{"intervention":254,"totalTrials":8,"cells":255},"CSL's 2010\u002F2011 Formulation of Enzira® Vaccine",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":273},{"trials":257,"activeCount":12},[],{"trials":259,"activeCount":12},[],{"trials":261,"activeCount":12},[],{"trials":263,"activeCount":12},[],{"trials":265,"activeCount":12},[266],{"nctId":267,"briefTitle":268,"status":99,"phases":269,"primaryCompletion":270,"completion":270,"start":270,"enrollment":150,"conditions":271,"interventions":272},"NCT01113580","A Clinical Trial of CSL's 2010\u002F2011 Formulation of Enzira® in a Healthy Adult Population",[45],"2010-05",[15],[254],{"trials":274,"activeCount":12},[],{"intervention":276,"totalTrials":8,"cells":277},"Enzira® vaccine",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":294},{"trials":279,"activeCount":12},[],{"trials":281,"activeCount":12},[],{"trials":283,"activeCount":12},[],{"trials":285,"activeCount":12},[],{"trials":287,"activeCount":12},[288],{"nctId":289,"briefTitle":290,"status":99,"phases":291,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":292,"interventions":293},"NCT01857297","A Study to Assess the Immunogenicity and Safety of CSL's 2013\u002F2014 Formulation of Enzira® Vaccine in Healthy Volunteers",[45],[18],[276],{"trials":295,"activeCount":12},[],{"intervention":177,"totalTrials":8,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":312},{"trials":299,"activeCount":12},[],{"trials":301,"activeCount":12},[],{"trials":303,"activeCount":12},[],{"trials":305,"activeCount":12},[],{"trials":307,"activeCount":12},[308],{"nctId":169,"briefTitle":170,"status":99,"phases":309,"primaryCompletion":172,"completion":173,"start":102,"enrollment":174,"conditions":310,"interventions":311},[45],[15],[156,177],{"trials":313,"activeCount":12},[],{"intervention":315,"totalTrials":8,"cells":316},"CSL Influenza Vaccine",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":335},{"trials":318,"activeCount":12},[],{"trials":320,"activeCount":12},[],{"trials":322,"activeCount":12},[],{"trials":324,"activeCount":12},[],{"trials":326,"activeCount":12},[327],{"nctId":328,"briefTitle":329,"status":99,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":150,"conditions":333,"interventions":334},"NCT01591837","A Study to Assess the Immunogenicity and Safety of CSL's 2012\u002F2013 Formulation of Enzira® Vaccine in Healthy Volunteers",[45],"2012-06","2012-05",[18],[315],{"trials":336,"activeCount":12},[],{"intervention":338,"totalTrials":8,"cells":339},"CSL Limited Influenza Vaccine",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":360},{"trials":341,"activeCount":12},[],{"trials":343,"activeCount":12},[],{"trials":345,"activeCount":12},[],{"trials":347,"activeCount":12},[],{"trials":349,"activeCount":12},[350],{"nctId":351,"briefTitle":352,"status":99,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT00562484","A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults",[45],"2009-11","2010-01","2008-03",7500,[15],[338],{"trials":361,"activeCount":12},[],{"intervention":363,"totalTrials":25,"cells":364},"QIVc",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":404,"NA":406},{"trials":366,"activeCount":12},[],{"trials":368,"activeCount":12},[],{"trials":370,"activeCount":12},[],{"trials":372,"activeCount":12},[373,383,393],{"nctId":374,"briefTitle":375,"status":99,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT03165617","Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to \u003C18 Years of Age",[44],"2019-09-30","2017-05-25",4514,[18],[363,382],"Non-influenza Comparator Vaccine",{"nctId":384,"briefTitle":385,"status":99,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":391},"NCT04074928","Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects",[44],"2020-09-03","2019-09-06",2414,[15,33,21],[363,392],"Comparator QIV",{"nctId":394,"briefTitle":395,"status":99,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT03932682","Efficacy Study With QIVc in Pediatric Subjects",[44],"2023-11-30","2024-02-13","2019-05-13",5723,[18],[363,403],"Comparator",{"trials":405,"activeCount":12},[],{"trials":407,"activeCount":12},[],{"intervention":392,"totalTrials":25,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":444,"NA":446},{"trials":411,"activeCount":12},[],{"trials":413,"activeCount":12},[],{"trials":415,"activeCount":12},[],{"trials":417,"activeCount":12},[418,429,433],{"nctId":419,"briefTitle":420,"status":99,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT02545543","A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age",[44],"2016-01","2016-06","2015-09",2278,[18],[428,392],"Seqirus QIV",{"nctId":384,"briefTitle":385,"status":99,"phases":430,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":431,"interventions":432},[44],[15,33,21],[363,392],{"nctId":434,"briefTitle":435,"status":99,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT05044195","A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age",[44],"2022-01-18","2022-09-09","2021-09-30",2044,[18],[443,392],"aQIV",{"trials":445,"activeCount":12},[],{"trials":447,"activeCount":12},[],{"intervention":449,"totalTrials":11,"cells":450},"Novartis Investigational H5N1 vaccine",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":479,"NA":481},{"trials":452,"activeCount":12},[],{"trials":454,"activeCount":12},[],{"trials":456,"activeCount":12},[],{"trials":458,"activeCount":12},[459,468],{"nctId":460,"briefTitle":461,"status":99,"phases":462,"primaryCompletion":136,"completion":136,"start":463,"enrollment":464,"conditions":465,"interventions":466},"NCT02091908","Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions",[44],"2014-04",540,[18],[449,449,467,467],"Novartis Seasonal Influenza Vaccine",{"nctId":469,"briefTitle":470,"status":99,"phases":471,"primaryCompletion":472,"completion":472,"start":463,"enrollment":473,"conditions":474,"interventions":478},"NCT02107807","Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine",[44],"2015-05",539,[18,475,476,15,477],"Flu, Human","Flu, Avian","Influenza A Virus, H5N1 Subtype",[449,449,467,467],{"trials":480,"activeCount":12},[],{"trials":482,"activeCount":12},[],{"intervention":467,"totalTrials":11,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":501,"NA":503},{"trials":486,"activeCount":12},[],{"trials":488,"activeCount":12},[],{"trials":490,"activeCount":12},[],{"trials":492,"activeCount":12},[493,497],{"nctId":460,"briefTitle":461,"status":99,"phases":494,"primaryCompletion":136,"completion":136,"start":463,"enrollment":464,"conditions":495,"interventions":496},[44],[18],[449,449,467,467],{"nctId":469,"briefTitle":470,"status":99,"phases":498,"primaryCompletion":472,"completion":472,"start":463,"enrollment":473,"conditions":499,"interventions":500},[44],[18,475,476,15,477],[449,449,467,467],{"trials":502,"activeCount":12},[],{"trials":504,"activeCount":12},[],{"intervention":403,"totalTrials":11,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":529,"NA":531},{"trials":508,"activeCount":12},[],{"trials":510,"activeCount":12},[],{"trials":512,"activeCount":12},[],{"trials":514,"activeCount":12},[515,525],{"nctId":516,"briefTitle":517,"status":518,"phases":519,"primaryCompletion":520,"completion":521,"start":520,"enrollment":12,"conditions":522,"interventions":523},"NCT04806529","An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older","WITHDRAWN",[43,44],"2020-12-15","2022-04-09",[15],[524,403],"Adjuvanted SARS-CoV-2 Subunit vaccine",{"nctId":394,"briefTitle":395,"status":99,"phases":526,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":527,"interventions":528},[44],[18],[363,403],{"trials":530,"activeCount":12},[],{"trials":532,"activeCount":12},[],{"intervention":534,"totalTrials":11,"cells":535},"Influenza Virus Vaccine",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":563,"NA":565},{"trials":537,"activeCount":12},[],{"trials":539,"activeCount":12},[],{"trials":541,"activeCount":12},[],{"trials":543,"activeCount":12},[544,554],{"nctId":545,"briefTitle":546,"status":99,"phases":547,"primaryCompletion":548,"completion":270,"start":549,"enrollment":550,"conditions":551,"interventions":552},"NCT00959049","A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population",[44],"2009-12","2009-09",1474,[15],[553,534],"CSL's Influenza Virus Vaccine",{"nctId":555,"briefTitle":556,"status":99,"phases":557,"primaryCompletion":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT00700193","A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population",[44],"2006-06","2005-03",298,[15],[534,534],{"trials":564,"activeCount":12},[],{"trials":566,"activeCount":12},[],{"intervention":568,"totalTrials":11,"cells":569},"Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":599,"NA":601},{"trials":571,"activeCount":12},[],{"trials":573,"activeCount":12},[],{"trials":575,"activeCount":12},[],{"trials":577,"activeCount":12},[578,590],{"nctId":579,"briefTitle":580,"status":99,"phases":581,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT01964989","Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.",[44],"2015-10","2016-08","2013-11",10644,[587],"Influenza Virus",[568,589],"Non-adjuvanted Trivalent Influenza Vaccine",{"nctId":591,"briefTitle":592,"status":99,"phases":593,"primaryCompletion":422,"completion":422,"start":594,"enrollment":595,"conditions":596,"interventions":597},"NCT02255409","Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05",[44],"2014-10",607,[15],[568,598],"non-adjuvanted Quadrivalent Influenza Vaccine",{"trials":600,"activeCount":12},[],{"trials":602,"activeCount":12},[],{"intervention":604,"totalTrials":11,"cells":605},"MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":636,"NA":638},{"trials":607,"activeCount":12},[],{"trials":609,"activeCount":12},[],{"trials":611,"activeCount":12},[],{"trials":613,"activeCount":12},[614,626],{"nctId":615,"briefTitle":616,"status":99,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT03314662","Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults",[44],"2017-12-11","2018-05-17","2017-10-17",1778,[18],[604,624,625],"Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine","MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain",{"nctId":627,"briefTitle":628,"status":99,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT02587221","Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age",[44],"2018-07-23","2016-09-30",6790,[15],[604,635],"Non-Influenza Comparator",{"trials":637,"activeCount":12},[],{"trials":639,"activeCount":12},[],{"intervention":641,"totalTrials":8,"cells":642},"Adjuvanted QIV",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":662,"NA":664},{"trials":644,"activeCount":12},[],{"trials":646,"activeCount":12},[],{"trials":648,"activeCount":12},[],{"trials":650,"activeCount":12},[651],{"nctId":652,"briefTitle":653,"status":99,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":660},"NCT02583256","Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)",[44],"2016-11-15","2017-05-09","2016-01-29",1601,[15],[641,661],"Non-adjuvanted QIV",{"trials":663,"activeCount":12},[],{"trials":665,"activeCount":12},[],{"intervention":661,"totalTrials":8,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":680,"NA":682},{"trials":669,"activeCount":12},[],{"trials":671,"activeCount":12},[],{"trials":673,"activeCount":12},[],{"trials":675,"activeCount":12},[676],{"nctId":652,"briefTitle":653,"status":99,"phases":677,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":678,"interventions":679},[44],[15],[641,661],{"trials":681,"activeCount":12},[],{"trials":683,"activeCount":12},[],{"intervention":685,"totalTrials":8,"cells":686},"Seqirus Quadrivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":706,"NA":708},{"trials":688,"activeCount":12},[],{"trials":690,"activeCount":12},[],{"trials":692,"activeCount":12},[],{"trials":694,"activeCount":12},[695],{"nctId":696,"briefTitle":697,"status":99,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":704},"NCT02914275","A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.",[44],"2017-03-09","2017-08-11","2016-09-27",2250,[18],[685,705],"Comparator Quadrivalent Inactivated Influenza Vaccine",{"trials":707,"activeCount":12},[],{"trials":709,"activeCount":12},[],{"intervention":705,"totalTrials":8,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":724,"NA":726},{"trials":713,"activeCount":12},[],{"trials":715,"activeCount":12},[],{"trials":717,"activeCount":12},[],{"trials":719,"activeCount":12},[720],{"nctId":696,"briefTitle":697,"status":99,"phases":721,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":722,"interventions":723},[44],[18],[685,705],{"trials":725,"activeCount":12},[],{"trials":727,"activeCount":12},[],{"intervention":524,"totalTrials":8,"cells":729},{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":742,"NA":744},{"trials":731,"activeCount":12},[],{"trials":733,"activeCount":12},[],{"trials":735,"activeCount":12},[],{"trials":737,"activeCount":12},[738],{"nctId":516,"briefTitle":517,"status":518,"phases":739,"primaryCompletion":520,"completion":521,"start":520,"enrollment":12,"conditions":740,"interventions":741},[43,44],[15],[524,403],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[],{"intervention":553,"totalTrials":8,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":760,"NA":762},{"trials":749,"activeCount":12},[],{"trials":751,"activeCount":12},[],{"trials":753,"activeCount":12},[],{"trials":755,"activeCount":12},[756],{"nctId":545,"briefTitle":546,"status":99,"phases":757,"primaryCompletion":548,"completion":270,"start":549,"enrollment":550,"conditions":758,"interventions":759},[44],[15],[553,534],{"trials":761,"activeCount":12},[],{"trials":763,"activeCount":12},[],{"intervention":382,"totalTrials":8,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":778,"NA":780},{"trials":767,"activeCount":12},[],{"trials":769,"activeCount":12},[],{"trials":771,"activeCount":12},[],{"trials":773,"activeCount":12},[774],{"nctId":374,"briefTitle":375,"status":99,"phases":775,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":776,"interventions":777},[44],[18],[363,382],{"trials":779,"activeCount":12},[],{"trials":781,"activeCount":12},[],{"intervention":141,"totalTrials":8,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":796,"NA":798},{"trials":785,"activeCount":12},[],{"trials":787,"activeCount":12},[],{"trials":789,"activeCount":12},[],{"trials":791,"activeCount":12},[792],{"nctId":132,"briefTitle":133,"status":99,"phases":793,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":794,"interventions":795},[44],[18],[141,90,90],{"trials":797,"activeCount":12},[],{"trials":799,"activeCount":12},[],{"intervention":589,"totalTrials":8,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":814,"NA":816},{"trials":803,"activeCount":12},[],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":12},[],{"trials":809,"activeCount":12},[810],{"nctId":579,"briefTitle":580,"status":99,"phases":811,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":812,"interventions":813},[44],[587],[568,589],{"trials":815,"activeCount":12},[],{"trials":817,"activeCount":12},[],{"intervention":428,"totalTrials":8,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":832,"NA":834},{"trials":821,"activeCount":12},[],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":12},[],{"trials":827,"activeCount":12},[828],{"nctId":419,"briefTitle":420,"status":99,"phases":829,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":830,"interventions":831},[44],[18],[428,392],{"trials":833,"activeCount":12},[],{"trials":835,"activeCount":12},[],{"intervention":837,"totalTrials":8,"cells":838},"aH5N1c",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":857,"NA":859},{"trials":840,"activeCount":12},[],{"trials":842,"activeCount":12},[],{"trials":844,"activeCount":12},[],{"trials":846,"activeCount":12},[847],{"nctId":848,"briefTitle":849,"status":99,"phases":850,"primaryCompletion":851,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":856},"NCT02839330","A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",[44],"2017-10-04","2016-07-11",3196,[855],"Avian Influenza",[837],{"trials":858,"activeCount":12},[],{"trials":860,"activeCount":12},[],{"intervention":624,"totalTrials":8,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":875,"NA":877},{"trials":864,"activeCount":12},[],{"trials":866,"activeCount":12},[],{"trials":868,"activeCount":12},[],{"trials":870,"activeCount":12},[871],{"nctId":615,"briefTitle":616,"status":99,"phases":872,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":873,"interventions":874},[44],[18],[604,624,625],{"trials":876,"activeCount":12},[],{"trials":878,"activeCount":12},[],{"intervention":625,"totalTrials":8,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":893,"NA":895},{"trials":882,"activeCount":12},[],{"trials":884,"activeCount":12},[],{"trials":886,"activeCount":12},[],{"trials":888,"activeCount":12},[889],{"nctId":615,"briefTitle":616,"status":99,"phases":890,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":891,"interventions":892},[44],[18],[604,624,625],{"trials":894,"activeCount":12},[],{"trials":896,"activeCount":12},[],{"intervention":898,"totalTrials":8,"cells":899},"Investigational aQIVc",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":920,"NA":922},{"trials":901,"activeCount":12},[],{"trials":903,"activeCount":12},[],{"trials":905,"activeCount":12},[],{"trials":907,"activeCount":12},[908],{"nctId":909,"briefTitle":910,"status":99,"phases":911,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":917},"NCT06015282","The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older",[44],"2024-03-05","2025-01-30","2023-11-03",7741,[18],[898,918,919],"licensed QIVr","licensed aQIV",{"trials":921,"activeCount":12},[],{"trials":923,"activeCount":12},[],{"intervention":918,"totalTrials":8,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":12},[],{"trials":929,"activeCount":12},[],{"trials":931,"activeCount":12},[],{"trials":933,"activeCount":12},[934],{"nctId":909,"briefTitle":910,"status":99,"phases":935,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":936,"interventions":937},[44],[18],[898,918,919],{"trials":939,"activeCount":12},[],{"trials":941,"activeCount":12},[],{"intervention":919,"totalTrials":8,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":956,"NA":958},{"trials":945,"activeCount":12},[],{"trials":947,"activeCount":12},[],{"trials":949,"activeCount":12},[],{"trials":951,"activeCount":12},[952],{"nctId":909,"briefTitle":910,"status":99,"phases":953,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":954,"interventions":955},[44],[18],[898,918,919],{"trials":957,"activeCount":12},[],{"trials":959,"activeCount":12},[],{"intervention":443,"totalTrials":8,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":963,"activeCount":12},[],{"trials":965,"activeCount":12},[],{"trials":967,"activeCount":12},[],{"trials":969,"activeCount":12},[970],{"nctId":434,"briefTitle":435,"status":99,"phases":971,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":972,"interventions":973},[44],[18],[443,392],{"trials":975,"activeCount":12},[],{"trials":977,"activeCount":12},[],{"intervention":598,"totalTrials":8,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":992,"NA":994},{"trials":981,"activeCount":12},[],{"trials":983,"activeCount":12},[],{"trials":985,"activeCount":12},[],{"trials":987,"activeCount":12},[988],{"nctId":591,"briefTitle":592,"status":99,"phases":989,"primaryCompletion":422,"completion":422,"start":594,"enrollment":595,"conditions":990,"interventions":991},[44],[15],[568,598],{"trials":993,"activeCount":12},[],{"trials":995,"activeCount":12},[],{"intervention":635,"totalTrials":8,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":12},[],{"trials":1001,"activeCount":12},[],{"trials":1003,"activeCount":12},[],{"trials":1005,"activeCount":12},[1006],{"nctId":627,"briefTitle":628,"status":99,"phases":1007,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":1008,"interventions":1009},[44],[15],[604,635],{"trials":1011,"activeCount":12},[],{"trials":1013,"activeCount":12},[],{"intervention":1015,"totalTrials":25,"cells":1016},"CSL425",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1018,"activeCount":12},[],{"trials":1020,"activeCount":12},[],{"trials":1022,"activeCount":12},[1023,1032,1042],{"nctId":1024,"briefTitle":1025,"status":99,"phases":1026,"primaryCompletion":549,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT00938639","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults",[43],"2010-03","2009-07",240,[29],[1015,1015],{"nctId":1033,"briefTitle":1034,"status":99,"phases":1035,"primaryCompletion":1036,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1041},"NCT00940108","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children",[43],"2009-10","2010-04","2009-08",370,[29],[1015,1015],{"nctId":1043,"briefTitle":1044,"status":99,"phases":1045,"primaryCompletion":354,"completion":1037,"start":1038,"enrollment":1046,"conditions":1047,"interventions":1048},"NCT00958126","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA",[43],1313,[15],[1015,1015],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"trials":1054,"activeCount":12},[],{"intervention":1056,"totalTrials":11,"cells":1057},"aH5N6c on Day 1",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1059,"activeCount":12},[],{"trials":1061,"activeCount":12},[],{"trials":1063,"activeCount":12},[1064,1078],{"nctId":1065,"briefTitle":1066,"status":99,"phases":1067,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT05874713","Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and\u002For H5N6 Influenza Vaccine in Adults",[43],"2024-04-25","2024-09-25","2023-06-07",480,[18,24,27,21,31],[1074,1056,1075,1076,1077],"aH5N8c on Day 1","aH5N8c on Day 22","aH5N6c on Day 22","aH5N8c on Day 202",{"nctId":1079,"briefTitle":1080,"status":99,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1091},"NCT05422326","A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed",[43],"2022-10-24","2023-03-24","2022-07-18",260,[18,1087,27,24,1088,1089,21,1090],"Influenza in Birds","Orthomyxoviridae Infections","RNA Virus Infections","Respiratory Tract Diseases",[1056,1076],{"trials":1093,"activeCount":12},[],{"trials":1095,"activeCount":12},[],{"trials":1097,"activeCount":12},[],{"intervention":1076,"totalTrials":11,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1101,"activeCount":12},[],{"trials":1103,"activeCount":12},[],{"trials":1105,"activeCount":12},[1106,1110],{"nctId":1065,"briefTitle":1066,"status":99,"phases":1107,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1108,"interventions":1109},[43],[18,24,27,21,31],[1074,1056,1075,1076,1077],{"nctId":1079,"briefTitle":1080,"status":99,"phases":1111,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1112,"interventions":1113},[43],[18,1087,27,24,1088,1089,21,1090],[1056,1076],{"trials":1115,"activeCount":12},[],{"trials":1117,"activeCount":12},[],{"trials":1119,"activeCount":12},[],{"intervention":1121,"totalTrials":11,"cells":1122},"Pandemic Influenza Vaccine",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1137,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1124,"activeCount":12},[],{"trials":1126,"activeCount":12},[1127],{"nctId":1128,"briefTitle":1129,"status":99,"phases":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT00136331","Study of a Pandemic Influenza Vaccine",[42],"2006-11","2005-10",400,[15],[1136],"Pandemic influenza vaccine",{"trials":1138,"activeCount":12},[1139],{"nctId":1140,"briefTitle":1141,"status":99,"phases":1142,"completion":1143,"start":1144,"enrollment":1133,"conditions":1145,"interventions":1146},"NCT00320346","Phase II Study of Pandemic Influenza Vaccine",[43],"2006-09","2006-07",[15],[1121],{"trials":1148,"activeCount":12},[],{"trials":1150,"activeCount":12},[],{"trials":1152,"activeCount":12},[],{"intervention":1154,"totalTrials":11,"cells":1155},"H5N1 pandemic influenza vaccine",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1157,"activeCount":12},[],{"trials":1159,"activeCount":12},[],{"trials":1161,"activeCount":12},[1162,1170],{"nctId":1163,"briefTitle":1164,"status":99,"phases":1165,"completion":1166,"start":1143,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT00370864","Study of a Pandemic Influenza Vaccine in Children",[43],"2007-07",220,[15],[1154],{"nctId":1171,"briefTitle":1172,"status":99,"phases":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1178},"NCT00376402","Study of a Pandemic Influenza Vaccine in Elderly Participants",[43],"2007-06","2006-10",200,[15],[1179],"H5N1 Pandemic Influenza Vaccine",{"trials":1181,"activeCount":12},[],{"trials":1183,"activeCount":12},[],{"trials":1185,"activeCount":12},[],{"intervention":1074,"totalTrials":8,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":12},[],{"trials":1191,"activeCount":12},[],{"trials":1193,"activeCount":12},[1194],{"nctId":1065,"briefTitle":1066,"status":99,"phases":1195,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1196,"interventions":1197},[43],[18,24,27,21,31],[1074,1056,1075,1076,1077],{"trials":1199,"activeCount":12},[],{"trials":1201,"activeCount":12},[],{"trials":1203,"activeCount":12},[],{"intervention":1075,"totalTrials":8,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":12},[],{"trials":1209,"activeCount":12},[],{"trials":1211,"activeCount":12},[1212],{"nctId":1065,"briefTitle":1066,"status":99,"phases":1213,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1214,"interventions":1215},[43],[18,24,27,21,31],[1074,1056,1075,1076,1077],{"trials":1217,"activeCount":12},[],{"trials":1219,"activeCount":12},[],{"trials":1221,"activeCount":12},[],{"intervention":1077,"totalTrials":8,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":12},[],{"trials":1227,"activeCount":12},[],{"trials":1229,"activeCount":12},[1230],{"nctId":1065,"briefTitle":1066,"status":99,"phases":1231,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1232,"interventions":1233},[43],[18,24,27,21,31],[1074,1056,1075,1076,1077],{"trials":1235,"activeCount":12},[],{"trials":1237,"activeCount":12},[],{"trials":1239,"activeCount":12},[],{"intervention":1241,"totalTrials":8,"cells":1242},"Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1244,"activeCount":12},[],{"trials":1246,"activeCount":12},[],{"trials":1248,"activeCount":12},[1249],{"nctId":1250,"briefTitle":1251,"status":99,"phases":1252,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT05501561","Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",[43],"2023-03-31","2022-08-25",1056,[18],[1241,1258,1259,1260],"Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1","Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1","Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1",{"trials":1262,"activeCount":12},[],{"trials":1264,"activeCount":12},[],{"trials":1266,"activeCount":12},[],{"intervention":1258,"totalTrials":8,"cells":1268},{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1270,"activeCount":12},[],{"trials":1272,"activeCount":12},[],{"trials":1274,"activeCount":12},[1275],{"nctId":1250,"briefTitle":1251,"status":99,"phases":1276,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":1255,"conditions":1277,"interventions":1278},[43],[18],[1241,1258,1259,1260],{"trials":1280,"activeCount":12},[],{"trials":1282,"activeCount":12},[],{"trials":1284,"activeCount":12},[],{"intervention":1259,"totalTrials":8,"cells":1286},{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1288,"activeCount":12},[],{"trials":1290,"activeCount":12},[],{"trials":1292,"activeCount":12},[1293],{"nctId":1250,"briefTitle":1251,"status":99,"phases":1294,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":1255,"conditions":1295,"interventions":1296},[43],[18],[1241,1258,1259,1260],{"trials":1298,"activeCount":12},[],{"trials":1300,"activeCount":12},[],{"trials":1302,"activeCount":12},[],{"intervention":1260,"totalTrials":8,"cells":1304},{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1306,"activeCount":12},[],{"trials":1308,"activeCount":12},[],{"trials":1310,"activeCount":12},[1311],{"nctId":1250,"briefTitle":1251,"status":99,"phases":1312,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":1255,"conditions":1313,"interventions":1314},[43],[18],[1241,1258,1259,1260],{"trials":1316,"activeCount":12},[],{"trials":1318,"activeCount":12},[],{"trials":1320,"activeCount":12},[],{"intervention":1322,"totalTrials":8,"cells":1323},"Investigational aIIV4c",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1325,"activeCount":12},[],{"trials":1327,"activeCount":12},[],{"trials":1329,"activeCount":12},[1330],{"nctId":1331,"briefTitle":1332,"status":99,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT04576702","Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults",[43],"2021-03-19","2021-05-24","2020-10-08",471,[15,33],[1322,1340,1341,1342],"IIV4c","aIIV4","RIV4",{"trials":1344,"activeCount":12},[],{"trials":1346,"activeCount":12},[],{"trials":1348,"activeCount":12},[],{"intervention":1340,"totalTrials":8,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1352,"activeCount":12},[],{"trials":1354,"activeCount":12},[],{"trials":1356,"activeCount":12},[1357],{"nctId":1331,"briefTitle":1332,"status":99,"phases":1358,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1359,"interventions":1360},[43],[15,33],[1322,1340,1341,1342],{"trials":1362,"activeCount":12},[],{"trials":1364,"activeCount":12},[],{"trials":1366,"activeCount":12},[],{"intervention":1341,"totalTrials":8,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1370,"activeCount":12},[],{"trials":1372,"activeCount":12},[],{"trials":1374,"activeCount":12},[1375],{"nctId":1331,"briefTitle":1332,"status":99,"phases":1376,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1377,"interventions":1378},[43],[15,33],[1322,1340,1341,1342],{"trials":1380,"activeCount":12},[],{"trials":1382,"activeCount":12},[],{"trials":1384,"activeCount":12},[],{"intervention":1342,"totalTrials":8,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":12},[],{"trials":1390,"activeCount":12},[],{"trials":1392,"activeCount":12},[1393],{"nctId":1331,"briefTitle":1332,"status":99,"phases":1394,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1395,"interventions":1396},[43],[15,33],[1322,1340,1341,1342],{"trials":1398,"activeCount":12},[],{"trials":1400,"activeCount":12},[],{"trials":1402,"activeCount":12},[],{"intervention":1404,"totalTrials":8,"cells":1405},"CSL412",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1407,"activeCount":12},[],{"trials":1409,"activeCount":12},[],{"trials":1411,"activeCount":12},[1412],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1420},"NCT00479648","A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants",[43],"2007-08","2007-05",612,[15],[1404,1421],"Inactivated trivalent influenza vaccine",{"trials":1423,"activeCount":12},[],{"trials":1425,"activeCount":12},[],{"trials":1427,"activeCount":12},[],{"intervention":1421,"totalTrials":8,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1431,"activeCount":12},[],{"trials":1433,"activeCount":12},[],{"trials":1435,"activeCount":12},[1436],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1437,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1438,"interventions":1439},[43],[15],[1404,1421],{"trials":1441,"activeCount":12},[],{"trials":1443,"activeCount":12},[],{"trials":1445,"activeCount":12},[],{"intervention":1447,"totalTrials":8,"cells":1448},"CSL's 2009 H1N1 Influenza Vaccine",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1450,"activeCount":12},[],{"trials":1452,"activeCount":12},[],{"trials":1454,"activeCount":12},[1455],{"nctId":1456,"briefTitle":1457,"status":99,"phases":1458,"primaryCompletion":354,"completion":1037,"start":1038,"enrollment":1459,"conditions":1460,"interventions":1461},"NCT00958243","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA",[43],473,[15],[1447,1447],{"trials":1463,"activeCount":12},[],{"trials":1465,"activeCount":12},[],{"trials":1467,"activeCount":12},[],{"intervention":128,"totalTrials":8,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":12},[],{"trials":1473,"activeCount":12},[],{"trials":1475,"activeCount":12},[1476],{"nctId":118,"briefTitle":119,"status":99,"phases":1477,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1478,"interventions":1479},[42,43],[15],[127,128],{"trials":1481,"activeCount":12},[],{"trials":1483,"activeCount":12},[],{"trials":1485,"activeCount":12},[],{"intervention":1487,"totalTrials":8,"cells":1488},"H5N1 antigen combined with MF59 adjuvant",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1504,"PHASE4":1506,"NA":1508},{"trials":1490,"activeCount":12},[],{"trials":1492,"activeCount":12},[],{"trials":1494,"activeCount":12},[1495],{"nctId":1496,"briefTitle":1497,"status":99,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1503},"NCT04669691","A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine",[43],"2022-04-15","2020-12-19",420,[18],[1487],{"trials":1505,"activeCount":12},[],{"trials":1507,"activeCount":12},[],{"trials":1509,"activeCount":12},[],{"intervention":1511,"totalTrials":8,"cells":1512},"aQII-1",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1514,"activeCount":12},[],{"trials":1516,"activeCount":12},[],{"trials":1518,"activeCount":12},[1519],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1522,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1528},"NCT04782323","Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults",[43],"2021-09-22","2022-03-03","2021-04-13",839,[15],[1511,1529,1530,1531,1532,1533,1534],"aQII-3 Investigational","aQII-6 Investigational","aQII-9 Investigational","aQII-10 Investigational","aQII-11 Investigational","Licensed QII Active Comparator",{"trials":1536,"activeCount":12},[],{"trials":1538,"activeCount":12},[],{"trials":1540,"activeCount":12},[],{"intervention":1529,"totalTrials":8,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1547,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1544,"activeCount":12},[],{"trials":1546,"activeCount":12},[],{"trials":1548,"activeCount":12},[1549],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1550,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1551,"interventions":1552},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1554,"activeCount":12},[],{"trials":1556,"activeCount":12},[],{"trials":1558,"activeCount":12},[],{"intervention":1530,"totalTrials":8,"cells":1560},{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1562,"activeCount":12},[],{"trials":1564,"activeCount":12},[],{"trials":1566,"activeCount":12},[1567],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1568,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1569,"interventions":1570},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1572,"activeCount":12},[],{"trials":1574,"activeCount":12},[],{"trials":1576,"activeCount":12},[],{"intervention":1531,"totalTrials":8,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1580,"activeCount":12},[],{"trials":1582,"activeCount":12},[],{"trials":1584,"activeCount":12},[1585],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1586,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1587,"interventions":1588},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1590,"activeCount":12},[],{"trials":1592,"activeCount":12},[],{"trials":1594,"activeCount":12},[],{"intervention":1532,"totalTrials":8,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1598,"activeCount":12},[],{"trials":1600,"activeCount":12},[],{"trials":1602,"activeCount":12},[1603],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1604,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1605,"interventions":1606},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1608,"activeCount":12},[],{"trials":1610,"activeCount":12},[],{"trials":1612,"activeCount":12},[],{"intervention":1533,"totalTrials":8,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1616,"activeCount":12},[],{"trials":1618,"activeCount":12},[],{"trials":1620,"activeCount":12},[1621],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1622,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1623,"interventions":1624},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1626,"activeCount":12},[],{"trials":1628,"activeCount":12},[],{"trials":1630,"activeCount":12},[],{"intervention":1534,"totalTrials":8,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":12},[],{"trials":1636,"activeCount":12},[],{"trials":1638,"activeCount":12},[1639],{"nctId":1520,"briefTitle":1521,"status":99,"phases":1640,"primaryCompletion":1523,"completion":1524,"start":1525,"enrollment":1526,"conditions":1641,"interventions":1642},[43],[15],[1511,1529,1530,1531,1532,1533,1534],{"trials":1644,"activeCount":12},[],{"trials":1646,"activeCount":12},[],{"trials":1648,"activeCount":12},[],{"intervention":1650,"totalTrials":8,"cells":1651},"sa-mRNA vaccine Dose 1",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1667,"PHASE3":1669,"PHASE4":1671,"NA":1673},{"trials":1653,"activeCount":12},[],{"trials":1655,"activeCount":12},[1656],{"nctId":1657,"briefTitle":1658,"status":99,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1664},"NCT06028347","Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults",[42],"2024-10-13","2023-10-05",96,[18],[1650,1665,1666],"sa-mRNA vaccine Dose 2","sa-mRNA vaccine Dose 3",{"trials":1668,"activeCount":12},[],{"trials":1670,"activeCount":12},[],{"trials":1672,"activeCount":12},[],{"trials":1674,"activeCount":12},[],{"intervention":1665,"totalTrials":8,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1691},{"trials":1678,"activeCount":12},[],{"trials":1680,"activeCount":12},[1681],{"nctId":1657,"briefTitle":1658,"status":99,"phases":1682,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1683,"interventions":1684},[42],[18],[1650,1665,1666],{"trials":1686,"activeCount":12},[],{"trials":1688,"activeCount":12},[],{"trials":1690,"activeCount":12},[],{"trials":1692,"activeCount":12},[],{"intervention":1666,"totalTrials":8,"cells":1694},{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1696,"activeCount":12},[],{"trials":1698,"activeCount":12},[1699],{"nctId":1657,"briefTitle":1658,"status":99,"phases":1700,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1701,"interventions":1702},[42],[18],[1650,1665,1666],{"trials":1704,"activeCount":12},[],{"trials":1706,"activeCount":12},[],{"trials":1708,"activeCount":12},[],{"trials":1710,"activeCount":12},[],{"intervention":1712,"totalTrials":8,"cells":1713},"Low dose A\u002FH2N3c + standard dose MF59",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1732,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1715,"activeCount":12},[],{"trials":1717,"activeCount":12},[1718],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT05875961","Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults",[42],"2024-11-15","2023-06-15",600,[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],"Intermediate dose A\u002FH2N3c + standard dose MF59","High dose A\u002FH2N3c + standard dose MF59","High dose A\u002FH2N3c non-adjuvanted","Lowest dose A\u002FH2N3c + high dose MF59","Low dose A\u002FH2N3c + high dose MF59",{"trials":1733,"activeCount":12},[],{"trials":1735,"activeCount":12},[],{"trials":1737,"activeCount":12},[],{"trials":1739,"activeCount":12},[],{"intervention":1727,"totalTrials":8,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":12},[],{"trials":1745,"activeCount":12},[1746],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1747,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1748,"interventions":1749},[42],[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],{"trials":1751,"activeCount":12},[],{"trials":1753,"activeCount":12},[],{"trials":1755,"activeCount":12},[],{"trials":1757,"activeCount":12},[],{"intervention":1728,"totalTrials":8,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":12},[],{"trials":1763,"activeCount":12},[1764],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1765,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1766,"interventions":1767},[42],[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],{"trials":1769,"activeCount":12},[],{"trials":1771,"activeCount":12},[],{"trials":1773,"activeCount":12},[],{"trials":1775,"activeCount":12},[],{"intervention":1729,"totalTrials":8,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":12},[],{"trials":1781,"activeCount":12},[1782],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1783,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1784,"interventions":1785},[42],[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],{"trials":1787,"activeCount":12},[],{"trials":1789,"activeCount":12},[],{"trials":1791,"activeCount":12},[],{"trials":1793,"activeCount":12},[],{"intervention":1730,"totalTrials":8,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1797,"activeCount":12},[],{"trials":1799,"activeCount":12},[1800],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1801,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1802,"interventions":1803},[42],[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],{"trials":1805,"activeCount":12},[],{"trials":1807,"activeCount":12},[],{"trials":1809,"activeCount":12},[],{"trials":1811,"activeCount":12},[],{"intervention":1731,"totalTrials":8,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1822,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":12},[],{"trials":1817,"activeCount":12},[1818],{"nctId":1719,"briefTitle":1720,"status":99,"phases":1819,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1820,"interventions":1821},[42],[18,24,27,21,31],[1712,1727,1728,1729,1730,1731],{"trials":1823,"activeCount":12},[],{"trials":1825,"activeCount":12},[],{"trials":1827,"activeCount":12},[],{"trials":1829,"activeCount":12},[],{"intervention":1831,"totalTrials":8,"cells":1832},"Adjuvanted, trivalent subunit influenza vaccine",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1834,"activeCount":12},[],{"trials":1836,"activeCount":12},[1837],{"nctId":1838,"briefTitle":1839,"status":99,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":121,"enrollment":1842,"conditions":1843,"interventions":1844},"NCT02126761","Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above",[42],"2015-11",196,[15],[1831,1845,1846,1847],"Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine","Antigen level modified adjuvanted, trivalent subunit influenza vaccine","Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine",{"trials":1849,"activeCount":12},[],{"trials":1851,"activeCount":12},[],{"trials":1853,"activeCount":12},[],{"trials":1855,"activeCount":12},[],{"intervention":1845,"totalTrials":8,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1859,"activeCount":12},[],{"trials":1861,"activeCount":12},[1862],{"nctId":1838,"briefTitle":1839,"status":99,"phases":1863,"primaryCompletion":1841,"completion":1841,"start":121,"enrollment":1842,"conditions":1864,"interventions":1865},[42],[15],[1831,1845,1846,1847],{"trials":1867,"activeCount":12},[],{"trials":1869,"activeCount":12},[],{"trials":1871,"activeCount":12},[],{"trials":1873,"activeCount":12},[],{"intervention":1846,"totalTrials":8,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1877,"activeCount":12},[],{"trials":1879,"activeCount":12},[1880],{"nctId":1838,"briefTitle":1839,"status":99,"phases":1881,"primaryCompletion":1841,"completion":1841,"start":121,"enrollment":1842,"conditions":1882,"interventions":1883},[42],[15],[1831,1845,1846,1847],{"trials":1885,"activeCount":12},[],{"trials":1887,"activeCount":12},[],{"trials":1889,"activeCount":12},[],{"trials":1891,"activeCount":12},[],{"intervention":1847,"totalTrials":8,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1902,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":12},[],{"trials":1897,"activeCount":12},[1898],{"nctId":1838,"briefTitle":1839,"status":99,"phases":1899,"primaryCompletion":1841,"completion":1841,"start":121,"enrollment":1842,"conditions":1900,"interventions":1901},[42],[15],[1831,1845,1846,1847],{"trials":1903,"activeCount":12},[],{"trials":1905,"activeCount":12},[],{"trials":1907,"activeCount":12},[],{"trials":1909,"activeCount":12},[],{"intervention":106,"totalTrials":8,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1913,"activeCount":12},[],{"trials":1915,"activeCount":12},[1916],{"nctId":97,"briefTitle":98,"status":99,"phases":1917,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":1918,"interventions":1919},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":1921,"activeCount":12},[],{"trials":1923,"activeCount":12},[],{"trials":1925,"activeCount":12},[],{"trials":1927,"activeCount":12},[],{"intervention":107,"totalTrials":8,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":12},[],{"trials":1933,"activeCount":12},[1934],{"nctId":97,"briefTitle":98,"status":99,"phases":1935,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":1936,"interventions":1937},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":1939,"activeCount":12},[],{"trials":1941,"activeCount":12},[],{"trials":1943,"activeCount":12},[],{"trials":1945,"activeCount":12},[],{"intervention":108,"totalTrials":8,"cells":1947},{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1949,"activeCount":12},[],{"trials":1951,"activeCount":12},[1952],{"nctId":97,"briefTitle":98,"status":99,"phases":1953,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":1954,"interventions":1955},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":1957,"activeCount":12},[],{"trials":1959,"activeCount":12},[],{"trials":1961,"activeCount":12},[],{"trials":1963,"activeCount":12},[],{"intervention":109,"totalTrials":8,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":12},[],{"trials":1969,"activeCount":12},[1970],{"nctId":97,"briefTitle":98,"status":99,"phases":1971,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":1972,"interventions":1973},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":1975,"activeCount":12},[],{"trials":1977,"activeCount":12},[],{"trials":1979,"activeCount":12},[],{"trials":1981,"activeCount":12},[],{"intervention":110,"totalTrials":8,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":12},[],{"trials":1987,"activeCount":12},[1988],{"nctId":97,"briefTitle":98,"status":99,"phases":1989,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":1990,"interventions":1991},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":1993,"activeCount":12},[],{"trials":1995,"activeCount":12},[],{"trials":1997,"activeCount":12},[],{"trials":1999,"activeCount":12},[],{"intervention":111,"totalTrials":8,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2003,"activeCount":12},[],{"trials":2005,"activeCount":12},[2006],{"nctId":97,"briefTitle":98,"status":99,"phases":2007,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":2008,"interventions":2009},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":2011,"activeCount":12},[],{"trials":2013,"activeCount":12},[],{"trials":2015,"activeCount":12},[],{"trials":2017,"activeCount":12},[],{"intervention":112,"totalTrials":8,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2028,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2021,"activeCount":12},[],{"trials":2023,"activeCount":12},[2024],{"nctId":97,"briefTitle":98,"status":99,"phases":2025,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":2026,"interventions":2027},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":2029,"activeCount":12},[],{"trials":2031,"activeCount":12},[],{"trials":2033,"activeCount":12},[],{"trials":2035,"activeCount":12},[],{"intervention":113,"totalTrials":8,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":12},[],{"trials":2041,"activeCount":12},[2042],{"nctId":97,"briefTitle":98,"status":99,"phases":2043,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":2044,"interventions":2045},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":2047,"activeCount":12},[],{"trials":2049,"activeCount":12},[],{"trials":2051,"activeCount":12},[],{"trials":2053,"activeCount":12},[],{"intervention":114,"totalTrials":8,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2064,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2057,"activeCount":12},[],{"trials":2059,"activeCount":12},[2060],{"nctId":97,"briefTitle":98,"status":99,"phases":2061,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":2062,"interventions":2063},[42],[15],[90,106,107,108,109,110,111,112,113,114],{"trials":2065,"activeCount":12},[],{"trials":2067,"activeCount":12},[],{"trials":2069,"activeCount":12},[],{"trials":2071,"activeCount":12},[],{"intervention":2073,"totalTrials":8,"cells":2074},"Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2076,"activeCount":12},[],{"trials":2078,"activeCount":12},[2079],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2082,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2087},"NCT00812019","Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)",[42],"2010-11","2008-11",753,[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],"Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59","Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59",{"trials":2100,"activeCount":12},[],{"trials":2102,"activeCount":12},[],{"trials":2104,"activeCount":12},[],{"trials":2106,"activeCount":12},[],{"intervention":2088,"totalTrials":8,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":12},[],{"trials":2112,"activeCount":12},[2113],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2114,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2115,"interventions":2116},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2118,"activeCount":12},[],{"trials":2120,"activeCount":12},[],{"trials":2122,"activeCount":12},[],{"trials":2124,"activeCount":12},[],{"intervention":2089,"totalTrials":8,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":12},[],{"trials":2130,"activeCount":12},[2131],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2132,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2133,"interventions":2134},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2136,"activeCount":12},[],{"trials":2138,"activeCount":12},[],{"trials":2140,"activeCount":12},[],{"trials":2142,"activeCount":12},[],{"intervention":2090,"totalTrials":8,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2146,"activeCount":12},[],{"trials":2148,"activeCount":12},[2149],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2150,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2151,"interventions":2152},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2154,"activeCount":12},[],{"trials":2156,"activeCount":12},[],{"trials":2158,"activeCount":12},[],{"trials":2160,"activeCount":12},[],{"intervention":2091,"totalTrials":8,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":12},[],{"trials":2166,"activeCount":12},[2167],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2168,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2169,"interventions":2170},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2172,"activeCount":12},[],{"trials":2174,"activeCount":12},[],{"trials":2176,"activeCount":12},[],{"trials":2178,"activeCount":12},[],{"intervention":2092,"totalTrials":8,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":12},[],{"trials":2184,"activeCount":12},[2185],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2186,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2187,"interventions":2188},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2190,"activeCount":12},[],{"trials":2192,"activeCount":12},[],{"trials":2194,"activeCount":12},[],{"trials":2196,"activeCount":12},[],{"intervention":2093,"totalTrials":8,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":12},[],{"trials":2202,"activeCount":12},[2203],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2204,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2205,"interventions":2206},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2208,"activeCount":12},[],{"trials":2210,"activeCount":12},[],{"trials":2212,"activeCount":12},[],{"trials":2214,"activeCount":12},[],{"intervention":2094,"totalTrials":8,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2218,"activeCount":12},[],{"trials":2220,"activeCount":12},[2221],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2222,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2223,"interventions":2224},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2226,"activeCount":12},[],{"trials":2228,"activeCount":12},[],{"trials":2230,"activeCount":12},[],{"trials":2232,"activeCount":12},[],{"intervention":2095,"totalTrials":8,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2243,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2236,"activeCount":12},[],{"trials":2238,"activeCount":12},[2239],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2240,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2241,"interventions":2242},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2244,"activeCount":12},[],{"trials":2246,"activeCount":12},[],{"trials":2248,"activeCount":12},[],{"trials":2250,"activeCount":12},[],{"intervention":2096,"totalTrials":8,"cells":2252},{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2267},{"trials":2254,"activeCount":12},[],{"trials":2256,"activeCount":12},[2257],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2258,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2259,"interventions":2260},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2262,"activeCount":12},[],{"trials":2264,"activeCount":12},[],{"trials":2266,"activeCount":12},[],{"trials":2268,"activeCount":12},[],{"intervention":2097,"totalTrials":8,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2279,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2272,"activeCount":12},[],{"trials":2274,"activeCount":12},[2275],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2276,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2277,"interventions":2278},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2280,"activeCount":12},[],{"trials":2282,"activeCount":12},[],{"trials":2284,"activeCount":12},[],{"trials":2286,"activeCount":12},[],{"intervention":2098,"totalTrials":8,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2297,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2290,"activeCount":12},[],{"trials":2292,"activeCount":12},[2293],{"nctId":2080,"briefTitle":2081,"status":99,"phases":2294,"primaryCompletion":183,"completion":2083,"start":2084,"enrollment":2085,"conditions":2295,"interventions":2296},[42],[15],[2073,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098],{"trials":2298,"activeCount":12},[],{"trials":2300,"activeCount":12},[],{"trials":2302,"activeCount":12},[],{"trials":2304,"activeCount":12},[],{"intervention":2306,"totalTrials":8,"cells":2307},"Flucelvax",{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2309,"activeCount":12},[],{"trials":2311,"activeCount":12},[],{"trials":2313,"activeCount":12},[],{"trials":2315,"activeCount":12},[],{"trials":2317,"activeCount":12},[],{"trials":2319,"activeCount":12},[2320],{"nctId":2321,"briefTitle":2322,"status":518,"phases":2323,"primaryCompletion":2324,"completion":2324,"start":228,"enrollment":12,"conditions":2325,"interventions":2327},"NCT02258178","Flucelvax Pregnancy Registry",[],"2020-06",[2326],"Pregnant Women, Influenza",[2306],{"intervention":2329,"totalTrials":8,"cells":2330},"Afluria Influenza Vaccine",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[],{"trials":2336,"activeCount":12},[],{"trials":2338,"activeCount":12},[],{"trials":2340,"activeCount":12},[],{"trials":2342,"activeCount":12},[2343],{"nctId":2344,"briefTitle":2345,"status":99,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2353},"NCT03442582","Afluria Pregnancy Registry",[],"2021-09-14","2017-09-08",490,[18,2351,2352],"Pregnancy","Birth Defect",[2329],{"intervention":2355,"totalTrials":8,"cells":2356},"Flucelvax Trivalent Influenza Vaccine",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2361,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2358,"activeCount":12},[],{"trials":2360,"activeCount":12},[],{"trials":2362,"activeCount":12},[],{"trials":2364,"activeCount":12},[],{"trials":2366,"activeCount":12},[],{"trials":2368,"activeCount":12},[2369],{"nctId":2370,"briefTitle":2371,"status":99,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2377},"NCT03438487","Flucelvax (TIVc or QIVc) Pregnancy Registry",[],"2020-12-31","2017-09-01",692,[18,2351,2352],[2355,2378],"Flucelvax Quadrivalent Influenza Vaccine",{"intervention":2378,"totalTrials":8,"cells":2380},{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2382,"activeCount":12},[],{"trials":2384,"activeCount":12},[],{"trials":2386,"activeCount":12},[],{"trials":2388,"activeCount":12},[],{"trials":2390,"activeCount":12},[],{"trials":2392,"activeCount":12},[2393],{"nctId":2370,"briefTitle":2371,"status":99,"phases":2394,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2395,"interventions":2396},[],[18,2351,2352],[2355,2378]]